Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Novel quantification method for psilocin in brain tissues using liquid chromatography-tandem mass spectrometry

AI Summary
  • Chromatography-centred LC-MS/MS method resolves phospholipid and salt matrix effects via matrix dilution, shallow gradient, and diverter timing, achieving 0.05 ng mL-1 LLOQ with protein precipitation.
  • Method met bioanalytical validation criteria for selectivity, accuracy and precision, enabling reliable mouse brain quantification and comparison of psilocin from formulations.
  • Psilocybin produced higher brain psilocin at 10 minutes; co-crystal gave more sustained levels without significant difference; 4-HIAA was undetected.
Summarise with AI (MRCPsych/FRANZCP)

Anal Methods. 2026 Nov 18. doi: 10.1039/d6ay01614f. Online ahead of print.

ABSTRACT

Psilocin, the psychoactive metabolite of psilocybin, is emerging as a therapeutic agent for treatment-resistant depression and anxiety. Precise measurement of psilocin and its major metabolite, 4-hydroxyindole-3-acetic acid (4-HIAA), in the brain tissue is, therefore, essential for characterizing its pharmacokinetics and informing safe, evidence-based use. However, quantitative liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis of small molecules in brain tissues is challenged by high levels of endogenous phospholipids that can negatively affect peak shape, and residual salts that can suppress ionization, hence compromising method reproducibility. The objective of this study was to develop a new validated LC-MS/MS approach for quantifying psilocin in different brain sections by resolving matrix effects at the chromatographic and instrumental level. In fact, no fully validated LC-MS method currently exist to determine psilocin within its target organ. Rather than relying on sorbent-based phospholipid removal, we implemented a chromatography-centered approach comprising matrix dilution (1 : 9, homogenate : organic), reduced flow with a shallower gradient to separate analytes from phospholipid signals, and precise diverter-valve timing to divert salt-rich LC eluent to waste. These modifications allowed for achieving a 0.05 ng mL-1 lower limit of quantification (LLOQ) using merely a protein precipitation step. In addition, the method met bioanalytical validation criteria for selectivity, accuracy, and precision, enabling reliable quantification in mouse brain tissue. Comparison of psilocybin with a psilocin-psilocybin co-crystal formulation revealed no sex- or brain region-dependent differences in brain psilocin concentrations. Psilocybin-treated mice had higher brain psilocin concentrations at 10 min than co-crystal-treated mice. Co-crystal administration appeared to yield more sustained brain psilocin concentrations, although this difference was not statistically significant compared to the psilocybin group. Under the same experimental conditions, 4-HIAA was not detected, consistent with limited brain accumulation and rapid clearance within the sampled window.

PMID:43049361 | DOI:10.1039/d6ay01614f

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD